News

Nov 15 2018

November is Lung Cancer Awareness Month (LCAM). Auris is proud to raise awareness and support the education of lung cancer, a disease that kills more people than breast, colon and prostate cancer combined. Throughout the month on our social media, we share articles and interviews on lung cancer research and promote lung cancer survivor stories. View our infographic to learn quick facts of this deadly disease and the evolution of biopsy methods overs the years.

Oct 30 2018

CHICAGO (Ivanhoe Newswire) - Lung cancer kills more Americans than breast, prostate and colon cancer combined, and like other forms of cancer, the earlier it’s caught, the better chance patients have to survive. Now, a new device is helping doctors diagnose lung cancer in one minimally-invasive procedure.

Oct 22 2018

Massdevice features Auris Health’s ACCESS study results, which were first announced at CHEST 2018 in San Antonio, Texas by Dr. Alexander Chen from Washington University in St. Louis. This study was the follow-up to the REACH study, which focused on the Monarch Platform’s ability to reach deeper into the lung’s periphery. With the ACCESS study, eight investigators performed robotic-assisted procedures using the Monarch Platform on a cadaveric model designed to mimic a real-life bronchoscopy procedure.

Oct 11 2018

Dr Kyle Bramley is interviewed at CHEST about the study presented at CHEST by Alex Chen, M.D. on robotic assisted bronchscopic biopsy of peripheral pulmonary lesions in a cadaveric model with simulated tumor targets.

Oct 08 2018

Auris Health, Inc. announced the results of the Nodule Access study at the CHEST 2018 Annual Meeting in San Antonio. Alexander C. Chen, M.D., Director of Interventional Pulmonology at Washington University of St. Louis, shared the findings during the Late-Breaking Abstract session.

Jun 01 2018

Auris Health made the coveted CNBC Disruptor 50 List for 2018, making it one of the few healthcare companies to receive the honor. Each year CNBC features private companies of all types whose game-changing innovations are transforming how the world does business. Joining the ranks of Airbnb, Lyft, and SpaceX, Auris was honored for the innovative work it brings to bronchoscopic procedures with its Monarch Platform. The goal of Auris’s robotic technology is to enable more accurate diagnosis, and eventually treatment, of small and hard-to-reach nodules in the periphery of the lung.

May 15 2018

Auris announced its collaboration with NeuWave Medical, a subsidiary of Ethicon, Inc. and part of the Johnson & Johnson Medical Devices Companies this week. The goal is to enable robotically assisted bronchoscopic ablation of lesions in the lung. This cooperative development and commercialization agreement calls for a co-development of integrated systems for robotic control, navigation and application of microwave ablation delivered via bronchoscopes.

Apr 27 2018

The Monarch Platform made headlines for the first use of the technology at El Camino Hospital, located in Mountain View, California, as part of a clinical trial. El Camino’s clinical trial marks the first institution in the United States to use the Monarch Platform’s robotic technology for bronchoscopic procedures. Dr. Ganesh Krishna, the pulmonologist who performed the first case on March 30, 2018, believes the Monarch Platform marks a needed “paradigm shift” in the way physicians diagnose lung disease.

Apr 12 2018

The Taft Center for Clinical Research at El Camino Hospital, located in Mountain View, California, reported that its interventional pulmonology team successfully used the Auris Monarch Platform as part of a clinical trial. Using Auris’s innovative robotic bronchoscopy technology, the team was able to view the inside of the patient’s lungs and obtain a tissue sample. This marks the first procedure of its kind in the United States.

Apr 12 2018

Dr. Frederic Moll, CEO of Auris Health was featured in The Wall Street Journal in an article about Auris and its innovative technologies. Dr. Moll, a serial entrepreneur and surgical robotics visionary, helped pioneer Auris’s beginnings and has pushed for medical innovation for over 30 years. He co-founded his first start-up, Endotherapeutics Corp., in the 1980s, developing products for laparoscopic or minimally invasive surgery. Gil Kliman, an investor in Restoration Robotics (another one of Dr. Moll’s ventures), said of Dr. Moll’s drive for success: “He is the one human that will never be replaced by a robot. He won’t give up on things; he can push though the inevitable naysayers.”